Favorable Insurance Pricing for Bioequivalent Generics Now Terminated

Published: 2005-02-25 06:56:00

Updated: 2005-02-25 06:56:00

Effective February 22nd, the generic drugs approved for their bioequivalance are no longer subject to the favorable pricing provision by the government, in which their registrations to the National Health Insurance (NHI) would not receive the drug pricing at up to 80% of the highest price establi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK